Human Retroviral Infections: Immunological and Therapeutic Control
The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquire...
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Boston, MA
Springer US
2002
|
| Schriftenreihe: | Infectious Agents and Pathogenesis
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established "cure" for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability |
| Beschreibung: | 1 Online-Ressource (XXII, 368 p) |
| ISBN: | 9780306468193 |
| DOI: | 10.1007/b111099 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046149158 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190906s2002 |||| o||u| ||||||eng d | ||
| 020 | |a 9780306468193 |9 978-0-306-46819-3 | ||
| 024 | 7 | |a 10.1007/b111099 |2 doi | |
| 035 | |a (ZDB-2-SBL)978-0-306-46819-3 | ||
| 035 | |a (OCoLC)1118990454 | ||
| 035 | |a (DE-599)BVBBV046149158 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.9 |2 23 | |
| 084 | |a YD 8400 |0 (DE-625)153349:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Human Retroviral Infections |b Immunological and Therapeutic Control |c edited by Kenneth E. Ugen, Mauro Bendinelli, Herman Friedman |
| 264 | 1 | |a Boston, MA |b Springer US |c 2002 | |
| 300 | |a 1 Online-Ressource (XXII, 368 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Infectious Agents and Pathogenesis | |
| 520 | |a The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established "cure" for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability | ||
| 650 | 4 | |a Infectious Diseases | |
| 650 | 4 | |a Medical Microbiology | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Pathology | |
| 650 | 4 | |a Laboratory Medicine | |
| 650 | 4 | |a Anatomy | |
| 650 | 4 | |a Emerging infectious diseases | |
| 650 | 4 | |a Microbiology | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Pathology | |
| 650 | 4 | |a Medical laboratories | |
| 650 | 4 | |a Human anatomy | |
| 650 | 0 | 7 | |a Retroviren-Infektion |0 (DE-588)4209311-9 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Retroviren-Infektion |0 (DE-588)4209311-9 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a Ugen, Kenneth E. |4 edt | |
| 700 | 1 | |a Bendinelli, Mauro |4 edt | |
| 700 | 1 | |a Friedman, Herman |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781475781687 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780306462221 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781475781670 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/b111099 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SBL | ||
| 940 | 1 | |q ZDB-2-SBL_2000/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031529335 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1007/b111099 |l UBR01 |p ZDB-2-SBL |q ZDB-2-SBL_2000/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180490351017984 |
|---|---|
| any_adam_object | |
| author2 | Ugen, Kenneth E. Bendinelli, Mauro Friedman, Herman |
| author2_role | edt edt edt |
| author2_variant | k e u ke keu m b mb h f hf |
| author_facet | Ugen, Kenneth E. Bendinelli, Mauro Friedman, Herman |
| building | Verbundindex |
| bvnumber | BV046149158 |
| classification_rvk | YD 8400 |
| collection | ZDB-2-SBL |
| ctrlnum | (ZDB-2-SBL)978-0-306-46819-3 (OCoLC)1118990454 (DE-599)BVBBV046149158 |
| dewey-full | 616.9 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.9 |
| dewey-search | 616.9 |
| dewey-sort | 3616.9 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/b111099 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03698nmm a2200625zc 4500</leader><controlfield tag="001">BV046149158</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190906s2002 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780306468193</subfield><subfield code="9">978-0-306-46819-3</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/b111099</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SBL)978-0-306-46819-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1118990454</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046149158</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.9</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YD 8400</subfield><subfield code="0">(DE-625)153349:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Human Retroviral Infections</subfield><subfield code="b">Immunological and Therapeutic Control</subfield><subfield code="c">edited by Kenneth E. Ugen, Mauro Bendinelli, Herman Friedman</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boston, MA</subfield><subfield code="b">Springer US</subfield><subfield code="c">2002</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XXII, 368 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Infectious Agents and Pathogenesis</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established "cure" for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Infectious Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical Microbiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pathology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Laboratory Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anatomy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Emerging infectious diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Microbiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pathology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical laboratories</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Human anatomy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Retroviren-Infektion</subfield><subfield code="0">(DE-588)4209311-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Retroviren-Infektion</subfield><subfield code="0">(DE-588)4209311-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ugen, Kenneth E.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bendinelli, Mauro</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Friedman, Herman</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781475781687</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780306462221</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781475781670</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/b111099</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SBL_2000/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031529335</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/b111099</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">ZDB-2-SBL_2000/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046149158 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:35Z |
| institution | BVB |
| isbn | 9780306468193 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031529335 |
| oclc_num | 1118990454 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XXII, 368 p) |
| psigel | ZDB-2-SBL ZDB-2-SBL_2000/2004 ZDB-2-SBL ZDB-2-SBL_2000/2004 |
| publishDate | 2002 |
| publishDateSearch | 2002 |
| publishDateSort | 2002 |
| publisher | Springer US |
| record_format | marc |
| series2 | Infectious Agents and Pathogenesis |
| spelling | Human Retroviral Infections Immunological and Therapeutic Control edited by Kenneth E. Ugen, Mauro Bendinelli, Herman Friedman Boston, MA Springer US 2002 1 Online-Ressource (XXII, 368 p) txt rdacontent c rdamedia cr rdacarrier Infectious Agents and Pathogenesis The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established "cure" for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability Infectious Diseases Medical Microbiology Immunology Pathology Laboratory Medicine Anatomy Emerging infectious diseases Microbiology Medical laboratories Human anatomy Retroviren-Infektion (DE-588)4209311-9 gnd rswk-swf Retroviren-Infektion (DE-588)4209311-9 s 1\p DE-604 Ugen, Kenneth E. edt Bendinelli, Mauro edt Friedman, Herman edt Erscheint auch als Druck-Ausgabe 9781475781687 Erscheint auch als Druck-Ausgabe 9780306462221 Erscheint auch als Druck-Ausgabe 9781475781670 https://doi.org/10.1007/b111099 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Human Retroviral Infections Immunological and Therapeutic Control Infectious Diseases Medical Microbiology Immunology Pathology Laboratory Medicine Anatomy Emerging infectious diseases Microbiology Medical laboratories Human anatomy Retroviren-Infektion (DE-588)4209311-9 gnd |
| subject_GND | (DE-588)4209311-9 |
| title | Human Retroviral Infections Immunological and Therapeutic Control |
| title_auth | Human Retroviral Infections Immunological and Therapeutic Control |
| title_exact_search | Human Retroviral Infections Immunological and Therapeutic Control |
| title_full | Human Retroviral Infections Immunological and Therapeutic Control edited by Kenneth E. Ugen, Mauro Bendinelli, Herman Friedman |
| title_fullStr | Human Retroviral Infections Immunological and Therapeutic Control edited by Kenneth E. Ugen, Mauro Bendinelli, Herman Friedman |
| title_full_unstemmed | Human Retroviral Infections Immunological and Therapeutic Control edited by Kenneth E. Ugen, Mauro Bendinelli, Herman Friedman |
| title_short | Human Retroviral Infections |
| title_sort | human retroviral infections immunological and therapeutic control |
| title_sub | Immunological and Therapeutic Control |
| topic | Infectious Diseases Medical Microbiology Immunology Pathology Laboratory Medicine Anatomy Emerging infectious diseases Microbiology Medical laboratories Human anatomy Retroviren-Infektion (DE-588)4209311-9 gnd |
| topic_facet | Infectious Diseases Medical Microbiology Immunology Pathology Laboratory Medicine Anatomy Emerging infectious diseases Microbiology Medical laboratories Human anatomy Retroviren-Infektion |
| url | https://doi.org/10.1007/b111099 |
| work_keys_str_mv | AT ugenkennethe humanretroviralinfectionsimmunologicalandtherapeuticcontrol AT bendinellimauro humanretroviralinfectionsimmunologicalandtherapeuticcontrol AT friedmanherman humanretroviralinfectionsimmunologicalandtherapeuticcontrol |